Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylaxis for tuberculosis in Europe--ongoing research

G Carosi1, A Matteelli

  • 1Clinic of Infectious and Tropical Diseases, University of Brescia, Italy.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|April 1, 1996
PubMed
Summary

Preventive therapy for tuberculosis (TB) is crucial for individuals with human immunodeficiency virus (HIV). Isoniazid shows effectiveness, but new alternatives are needed due to toxicity and compliance issues.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to the Union's statement on ongoing conflicts and impact on health services.

IJTLD open·2026
Same author

Search for Axion Dark Matter from 1.1 to 1.3 GHz with ADMX.

Physical review letters·2025
Same author

Natural history of nonfunctioning pituitary microadenomas: a systematic review and individual participant data meta-analysis.

European journal of endocrinology·2025
Same author

ADMX Axion Dark Matter Bounds around 3.3  μeV with Dine-Fischler-Srednicki-Zhitnitsky Discovery Ability.

Physical review letters·2025
Same author

Cascade of care for TB infection in persons newly diagnosed with HIV in Italy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

TB prevention activities in the WHO European Region.

IJTLD open·2024

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Rising incidence of tuberculosis (TB) in patients with human immunodeficiency virus (HIV) infection necessitates preventive strategies.
  • HIV-related immunosuppression can lead to anergy, complicating tuberculosis screening using purified protein derivative (PPD) testing.
  • Identifying at-risk HIV-positive individuals for latent TB reactivation is a significant clinical challenge.

Purpose of the Study:

  • To review current strategies for PPD testing and treatment criteria for TB prevention in HIV-positive patients.
  • To evaluate the efficacy, risks, and benefits of isoniazid prophylaxis for TB in HIV-positive individuals.
  • To explore emerging alternative therapies for TB prevention in this high-risk population due to limitations of current treatments.

Main Methods:

Related Experiment Videos

  • Review of existing literature on TB prevention in HIV-positive patients.
  • Analysis of data from efficacy and feasibility trials of isoniazid prophylaxis.
  • Discussion of preliminary studies on newer TB preventive therapies.

Main Results:

  • Isoniazid is effective for TB prophylaxis in HIV-positive, PPD-positive patients.
  • Challenges with isoniazid include toxicity and patient compliance.
  • There is an ongoing need for alternative TB preventive therapies.

Conclusions:

  • Isoniazid is a viable option for TB prevention in certain HIV-positive individuals, but its use is limited by side effects and adherence issues.
  • Further research and development of alternative preventive therapies are essential to improve TB control in the HIV-positive population.
  • Optimized PPD testing strategies and clear treatment criteria are crucial for managing TB risk in HIV-infected patients.